autologous fully humanized CD22-CAR T cells

Autologous fully humanized CD22-CAR T cells (specifically the construct CD22-CARFH80, also known as CD22-BBz 80) are an investigational chimeric antigen receptor (CAR) T-cell therapy developed by Beijing Boren Hospital for the treatment of relapsed or refractory acute B lymphoblastic leukemia (B-ALL). The therapy utilizes patient-derived T cells genetically engineered to express a CAR containing a fully human single-chain variable fragment (scFv) targeting CD22, fused to a 4-1BB costimulatory domain and a CD3ζ signaling domain. By employing a fully human binder, the therapy aims to minimize immunogenicity and enhance persistence compared to murine-derived CARs, providing a potential salvage option for patients who have relapsed after prior CD19- or CD22-targeted therapies.

Other names

autologous fully humanized CD22-CAR T-cell therapyfully humanized CD22-CAR T cellsfully humanized CD22-targeted CAR-T cells